FREDERICK W DRISCOLL

CIK 1129890 · Chief Financial Officer · last filed 2026-07-08

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$9.6K

Companies

11

Total Filings

67

Lifetime Open-Market Net

-$1.30M

Filer Profile

Reported Address
C/O CELLECTAR BIOSCIENCES, INC.
3301 AGRICULTURE DRIVE
MADISON, WI 53716
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
CLRB Director 65 $2.31 $150 $20.2K 7 2026-07-08
LITS Director $1.11 $0 1 2025-11-18
Lite Strategy, Inc. (MEIP) Delisted Director 1,875 $3.20 $6.0K -$625 10 2025-07-17
CUE Director $28.74 $0 8 2025-01-03
Renovacor, Inc. (RCOR.WS) Delisted Chief Financial Officer $0.07 $0 1 2022-03-28
FLXN Chief Financial Officer 0 $24.62 $0 -$689.0K 14 2021-11-19
ImmunityBio, Inc. (NK) Delisted Director 124,535 -$668.1K 5 2020-08-13
Cellectar Biosciences, Inc. (CLRBZ) Delisted Director $0.12 $0 4 2020-06-25
Oncotelic Therapeutics, Inc. (OXGN) Delisted Director $0 4 2016-06-03
NVAX VP, CFO & Treasurer 1,000 $9.42 $9.4K $23.6K 7 2013-03-06
GENELABS TECHNOLOGIES INC /CA (GNLB) Delisted CEO 0 $10.0K 6 2009-01-07

Recent Filings · Page 2 of 7

67 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2022-08-01 CLRB Grant (A) $0 EDGAR
2022-07-07 Lite Strategy, Inc. (MEIP) Delisted Grant (A) $0 EDGAR
2022-03-28 Renovacor, Inc. (RCOR.WS) Delisted Grant (A) $0 EDGAR
2022-01-05 CUE Grant (A) $0 EDGAR
2021-11-19 FLXN Disp (D) −30,680 -$260.8K EDGAR
2021-09-07 CLRB Buy (P) +19,417 $20.2K EDGAR
2021-07-06 Lite Strategy, Inc. (MEIP) Delisted Grant (A) $0 EDGAR
2021-07-02 CLRB Grant (A) $0 EDGAR
2021-06-03 FLXN Grant (A) +28,000 $0 EDGAR
2021-02-24 Lite Strategy, Inc. (MEIP) Delisted Sell (S) −25,000 -$100.6K EDGAR
Showing 1120 of 67
Page 2 of 7
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.